Clinical trials: Paclitaxel, completed
Oral Cancer
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC).
- Trial name
- NCT00933387
- Testing
- Cetuximab,Paclitaxel,Cisplatin
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- National Health Research Institutes, Taiwan
Breast Cancer
Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating women with metastatic breast…
- Trial name
- NCT00003540
- Testing
- gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuropathic Pain, Chemotherapy Effect
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Phase IIa clinical trial will be conducted with patients requiring in-label paclitaxel-chemotherapy due to ovarian or breast cancer.
- Trial name
- PrevTel (NCT05322889)
- Testing
- Telmisartan tablets
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Dr. Frank Behrens
Non Small Cell Lung Cancer
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
This research is being done because further research on selumetinib in combination with standard chemotherapy treatment is needed.
- Trial name
- NCT01783197
- Testing
- Paclitaxel, Carboplatin, Selumetinib
- Where
- 4 sites in Canada
- Volunteers
- 39 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
Hormonal therapy is the standard treatment for prostate cancer which has spread to other areas of the body. Despite the high initial response rates to hormonal therapy, the vast majority of men will develop cancer which is no…
- Trial name
- NCT00151060
- Testing
- Estramustine, Etoposide, Paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Pancreatic Cancer
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer in conjunction with…
- Trial name
- NCT02559674
- Testing
- Gemcitabine, Nab-paclitaxel, ALT-803
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Altor BioScience
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Atherosclerosis, Coronary Artery Disease
ION US Post-Approval Study
The purpose of this study is to compile real-world clinical outcomes data for the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01422889
- Testing
- ION™ Coronary Stent System
- Where
- 40 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Boston Scientific Corporation
Bladder Cancer, Ureter Cancer
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Taxane-based chemotherapy is currently one of the most commonly used regimen for salvage chemotherapy in advanced urothelial carcinoma.
- Trial name
- NCT01426126
- Testing
- Genexol PM
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Asan Medical Center
Carcinoma, Squamous Cell, Head and Neck Neoplasms
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
The primary objective of this study is to evaluate whether genomic based risk-stratification can be used in deciding whether to de-intensify in patients with Human Papillomavirus (HPV)-associated Oropharyngeal Squamous Cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT03077243
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with…
- Trial name
- NCT01493843
- Testing
- pictilisib, bevacizumab, carboplatin
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 501 people
- Sponsor
- Genentech, Inc.
Critical Limb Ischemia, Peripheral Artery Disease
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
The aim of this observational study is to evaluate the outcomes and safety of the Paclitaxel-eluted balloon catheter ELUTAX SV for treatment of peripheral arterial disease (PAD) in below-the-knee vessels
- Trial name
- Apollo (NCT02539940)
- Testing
- Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV
- Where
- 10 sites in Germany
- Volunteers
- 166 people
- Sponsor
- Jena University Hospital
Sarcoma, Kaposi, HIV Infections
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour…
- Trial name
- NCT00002189
- Testing
- Paclitaxel
- Where
- United States
- Sponsor
- Baker Norton Pharmaceuticals
Esophagogastric Adenocarcinoma
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach.
- Trial name
- NCT03193918
- Testing
- Crenolanib, Ramucirumab, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
- Trial name
- NCT03840915
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 19 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Esophagus Cancer
Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma
Most ESCC received NAC in China without supportive evidence from local RCTs. The negative conclusion about NAC originated from Western countries in the 1990s.
- Trial name
- NCT05569668
- Testing
- Paclitaxel- and platinum-based chemotherapy
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Henan Cancer Hospital
Coronary Artery Disease
Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter
To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon
- Trial name
- SCBDENOVO (NCT03908450)
- Testing
- PTCA of coronary de novo lesion PCB, PTCA of coronary de novo lesion SCB
- Where
- 4 sites in Germany, Switzerland
- Volunteers
- 70 people
- Sponsor
- InnoRa GmbH
Non-metastatic Muscle Invasive Bladder Cancer
Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)
Open-label, interventional, multi-centre, randomized phase II study. Cancer studied is non-metastatic muscle invasive bladder cancer (MIBC).
- Trial name
- AURA (NCT03674424)
- Testing
- Avelumab, cystectomy, CG
- Where
- 10 sites in Belgium, France
- Volunteers
- 137 people
- Sponsor
- Jules Bordet Institute
Lung Cancer
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.
- Trial name
- NCT02513563
- Testing
- Carboplatin, Paclitaxel, AZD1775
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating patients with B-cell non-Hodgkin lymphoma that…
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma
- Trial name
- NCT03003546
- Testing
- Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.